#AI reads Urine# Untargeted metabolomic profiling of serum and urine in kidney cancer

This study conducted untargeted metabolomic analysis on serum and urine samples from 56 kidney cancer patients and 200 controls using ultra-high-performance liquid chromatography-ultra-high-resolution mass spectrometry (UHPLC-UHRMS) combined with multivariate statistical analysis. Significant metabolic abnormalities were found in kidney cancer patients involving lipid metabolism, amino acid biosynthesis, and glycerophospholipid metabolism pathways. Among them, 19 serum metabolites and 12 urine metabolites showed high diagnostic potential (AUC>0.9), providing evidence for the discovery of non-invasive biomarkers for kidney cancer. Further validation in larger cohorts is required to confirm their clinical value.

Metabolomics. 2025 Jul 1;21(4):97. doi: 10.1007/s11306-025-02294-4.

Untargeted metabolomic profiling of serum and urine in kidney cancer: a non-invasive approach for biomarker discovery

Youhe Gao

Statement: During the preparation of this work the author(s) used Doubao / AI reading for summarizing the content. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.

For earlier AI Reads Urine articles：

https://www.keaipublishing.com/en/journals/advances-in-biomarker-sciences-and-technology/ai-reads-urine/